Pharmacokinetics and Pharmacodynamics in Critical Care

Clinical Overview

Pharmacokinetics (PK) and pharmacodynamics (PD) are fundamentally altered in critically ill patients, leading to unpredictable drug exposure and treatment failures. Critical illness induces profound changes in volume of distribution (Vd), drug clearance (CL), protein binding, and receptor sensitivity. Sepsis increases Vd 2-3× for hydrophilic drugs due to capillary leak syndrome and fluid resuscitation. Augmented renal clearance (ARC) occurs in 20-65% of ICU patients, causing subtherapeutic antibiotic levels. Hypoalbuminemia (present in 30-50% of critically ill) increases free drug fraction of highly protein-bound agents. Failure to adjust dosing strategies results in therapeutic failure (under-dosing antibiotics, analgesics) or toxicity (over-dosing sedatives, anticoagulants). [1,2,3]

Traditional fixed-dose regimens designed for healthy volunteers do not account for the dynamic, patient-specific PK/PD changes in critical illness. Understanding these principles is essential for CICM Fellowship examinations and safe, effective prescribing in intensive care. [4,5]

---

Epidemiology and Burden

Prevalence of PK Alterations in Critical Illness:

• Augmented renal clearance (ARC): 20-65% of ICU patients, highest in young, obese, trauma, and burns patients (creatinine clearance greater than 130 mL/min/1.73 m²) [6,7]
• Hypoalbuminemia (below 25 g/L): 30-50% of critically ill patients, particularly sepsis and burns [8,9]
• Third-spacing and capillary leak: Universal in septic shock during first 48-72 hours, increases Vd 2-3× for hydrophilic drugs [10,11]
• Hepatic dysfunction: 10-40% of ICU patients have reduced drug metabolism due to hypoperfusion, inflammation, or primary liver disease [12]

Clinical Impact:

• Subtherapeutic antibiotic concentrations in 30-60% of ICU patients receiving standard dosing, contributing to treatment failure and antimicrobial resistance [13,14,15]
• Propofol infusion syndrome (PRIS) incidence 1-5% with prolonged infusion, mortality 18-48% [16]
• Vancomycin nephrotoxicity (V-AKI) in 5-35% of ICU patients, associated with AUC₀₋₂₄ greater than 600 mg·h/L [17,18]

---

Fundamental Pharmacokinetic Principles

1. Absorption (A)

Enteral Absorption in Critical Illness:

Oral and enteral absorption is unreliable in ICU patients due to:

• Reduced gastric emptying and gut motility: Opioids, vasopressors, and critical illness cause gastroparesis [19]
• Splanchnic hypoperfusion: Shock states reduce intestinal blood flow by 30-70%, impairing absorption [20]
• Enterocyte dysfunction: Sepsis, ischemia, and inflammatory cytokines damage absorptive surfaces [21]
• Altered gastric pH: Proton pump inhibitors (PPIs) reduce absorption of weak bases (e.g., ketoconazole, atazanavir) [22]

Clinical implications: Intravenous administration is preferred for critical drugs (antibiotics, anticonvulsants, vasopressors). Enteral absorption bioavailability may be 30-70% of normal. [23]

2. Distribution (D)

Volume of Distribution (Vd):

Vd represents the theoretical volume into which a drug distributes. It determines loading dose requirements.

Formula:

Vd = (Dose administered)/(Plasma concentration at time zero)

Factors Increasing Vd in Critical Illness:

Factors Decreasing Vd:

• Dehydration
• Loss of extracellular fluid (diuresis, burns)
• Reduced cardiac output limiting tissue perfusion

Clinical Pearl: Hydrophilic drugs (aminoglycosides, beta-lactams, vancomycin) have increased Vd in sepsis/fluid overload, requiring higher loading doses. Lipophilic drugs (propofol, fentanyl, midazolam) have minimal Vd change unless obesity is present. [29]

3. Metabolism (M)

Hepatic Metabolism in Critical Illness:

The liver is the primary site of drug metabolism via Phase I (cytochrome P450 oxidation) and Phase II (glucuronidation, sulfation) reactions.

Phase I Metabolism (CYP450):

• Reduced in critical illness by 20-60% due to:
  • Hepatic hypoperfusion in shock (reduced hepatic blood flow) [30]
  • Inflammatory cytokines (IL-6, TNF-α) down-regulate CYP450 expression [31]
  • Reduced hepatic oxygen delivery in ARDS, mechanical ventilation [32]

Clinical implications:

• Drugs metabolized by CYP450 (midazolam, fentanyl, propofol, metoprolol) have prolonged half-lives and accumulate with repeated dosing [33]
• Propofol infusion syndrome risk increases with prolonged use due to accumulation of toxic metabolites [16]

Phase II Metabolism (Glucuronidation):

• Relatively preserved in critical illness compared to Phase I [34]
• Morphine metabolized to morphine-6-glucuronide (active, renally excreted) and morphine-3-glucuronide (inactive) [35]

Hepatic Blood Flow-Dependent Clearance:

Drugs with high hepatic extraction ratios (greater than 0.7) depend on hepatic blood flow:

• Flow-limited drugs: Propofol, fentanyl, lidocaine, morphine [36]
• Reduced clearance in low cardiac output states, vasopressor use, or hepatic dysfunction [37]

4. Excretion (E)

Renal Excretion:

The kidneys eliminate hydrophilic drugs and active metabolites via glomerular filtration, tubular secretion, and tubular reabsorption.

Glomerular Filtration Rate (GFR) Alterations:

Augmented Renal Clearance (ARC):

ARC is defined as creatinine clearance greater than 130 mL/min/1.73 m² and occurs in 20-65% of critically ill patients due to:

• Hyperdynamic circulation (sepsis, trauma, burns)
• Young age (below 50 years)
• Obesity (increased nephron mass)
• Fluid resuscitation (increased renal blood flow) [6,7]

Consequences:

• Beta-lactam concentrations are subtherapeutic in 50-80% of patients with ARC [41]
• Vancomycin trough below 10 mg/L in 60% of ARC patients despite standard dosing [42]
• Increased risk of treatment failure and antimicrobial resistance [13]

Detection and Management:

• Measured 8-hour or 24-hour urine creatinine clearance (serum creatinine underestimates GFR in ARC) [43]
• Increase antibiotic doses or use extended/continuous infusions [44]

CRRT Drug Clearance:

CRRT removes drugs via:

• Convection (hemofiltration): Solute drag, depends on sieving coefficient (molecular weight below 30 kDa, unbound drug)
• Diffusion (hemodialysis): Concentration gradient across membrane
• Adsorption: Drug binding to CRRT membrane (minimal for most drugs)

Factors Affecting CRRT Clearance:

• Effluent dose: 20-25 mL/kg/h standard dose; higher doses increase drug removal [45]
• Protein binding: Highly protein-bound drugs (greater than 90%) are not effectively removed (e.g., propofol, ceftriaxone) [46]
• Vd: Drugs with large Vd (greater than 2 L/kg) are not significantly removed (e.g., amiodarone, digoxin) [47]

Drug Dosing in CRRT:

• Beta-lactams: Use standard to increased doses due to hydrophilicity and low protein binding (removed by CRRT) [48]
• Vancomycin: Loading dose 20-25 mg/kg, maintenance 15-20 mg/kg q12-24h, target AUC₀₋₂₄ 400-600 mg·h/L [18]
• Aminoglycosides: Extended interval dosing (5-7 mg/kg q24-48h) with TDM [49]

---

Protein Binding Alterations

Physiological Protein Binding:

Most drugs bind reversibly to plasma proteins (albumin for acidic drugs, alpha-1-acid glycoprotein [AAG] for basic drugs). Only unbound (free) drug is pharmacologically active and available for distribution, metabolism, and excretion. [50]

Hypoalbuminemia in Critical Illness:

• Albumin below 25 g/L in 30-50% of critically ill patients due to:
  • Reduced hepatic synthesis (inflammation, liver disease)
  • Capillary leak (sepsis, burns)
  • Dilution (fluid resuscitation) [8,9]

Clinical Consequences:

Alpha-1-Acid Glycoprotein (AAG):

AAG is an acute-phase reactant that increases in critical illness (inflammation, surgery, trauma). [55]

• Binds basic drugs (lidocaine, propranolol, fentanyl)
• Increased AAG reduces free drug fraction, potentially causing decreased efficacy [56]

Interpretation of Drug Levels:

• For highly protein-bound drugs (greater than 80% binding), measure free (unbound) drug levels in hypoalbuminemia to guide dosing [57]
• Total drug concentration may be therapeutic, but free concentration is supratherapeutic (phenytoin) or subtherapeutic (ceftriaxone) [26]

---

Altered Clearance in Organ Dysfunction

Renal Impairment

Creatinine Clearance Estimation:

Traditional equations (Cockcroft-Gault, MDRD, CKD-EPI) underestimate GFR in critically ill patients due to:

• Increased creatinine generation (muscle catabolism, rhabdomyolysis)
• Reduced creatinine generation (muscle wasting, reduced dietary intake)
• Tubular secretion of creatinine (overestimates GFR by 10-40%) [58]

Gold Standard: Measured urine creatinine clearance (8-hour or 24-hour collection), but impractical in unstable patients. [59]

Dose Adjustments in AKI:

Hepatic Impairment

Child-Pugh Classification and Drug Dosing:

• Child-Pugh A: Minimal dose adjustment
• Child-Pugh B: Reduce dose 25-50% for hepatically metabolized drugs
• Child-Pugh C: Avoid hepatically metabolized drugs or reduce dose 50-75%; consider alternatives [63]

Drugs Requiring Dose Reduction:

• Benzodiazepines: Midazolam, lorazepam (prolonged sedation, encephalopathy risk) [64]
• Opioids: Morphine, fentanyl (accumulation of active metabolites) [65]
• Beta-blockers: Propranolol, metoprolol (reduced first-pass metabolism) [66]
• Propofol: Risk of PRIS and hyperlipidemia; limit to below 4 mg/kg/hr [16]

Drugs to Avoid in Severe Hepatic Impairment:

• Valproate (hepatotoxicity)
• Paracetamol greater than 2 g/day (hepatotoxicity risk)
• Haloperidol (QT prolongation)
• NSAIDs (bleeding, renal impairment) [67]

---

Pharmacodynamic Principles

Pharmacodynamics describes the relationship between drug concentration and effect. Understanding PD is critical for optimizing therapeutic outcomes and avoiding toxicity.

1. Dose-Response Relationships

Emax Model:

The Emax model describes the relationship between drug concentration and effect:

E = E_0 + \frac{Emax × C}{EC50 + C}

Where:

• E: Effect at concentration C
• E₀: Baseline effect (no drug)
• Emax: Maximum achievable effect
• EC₅₀: Concentration producing 50% of Emax
• C: Drug concentration

Clinical Application:

• Vasopressors: Norepinephrine dose-response curve is steep; small dose changes cause large BP changes [68]
• Sedatives: Propofol demonstrates sigmoid Emax relationship; oversedation occurs above EC₉₀ [69]
• Antibiotics: Beta-lactams exhibit time-dependent killing; effect saturates above MIC [70]

2. Concentration-Dependent vs Time-Dependent Killing

Concentration-Dependent Antibiotics:

• Mechanism: Bactericidal activity increases with peak concentration (Cmax/MIC ratio)
• Examples: Aminoglycosides, fluoroquinolones, daptomycin
• Dosing Strategy: High-dose, extended interval dosing to maximize Cmax/MIC greater than 8-10 [71,72]
• Post-Antibiotic Effect (PAE): Persistent bacterial suppression after drug concentration falls below MIC (4-12 hours for aminoglycosides) [73]

Time-Dependent Antibiotics:

• Mechanism: Bactericidal activity depends on time above MIC (%T>MIC)
• Examples: Beta-lactams (penicillins, cephalosporins, carbapenems)
• Dosing Strategy: Extended or continuous infusion to maximize %T>MIC greater than 40-70% [70,74]
• PK/PD Target: %T>MIC 40% for bacteriostatic, 60-70% for bactericidal effect [75]

AUC/MIC-Dependent Antibiotics:

• Mechanism: Total drug exposure (AUC₀₋₂₄) relative to MIC
• Examples: Vancomycin, fluoroquinolones, linezolid
• Dosing Strategy: Target AUC₀₋₂₄/MIC greater than 400 for vancomycin [18,76]

3. Receptor Theory and Tolerance

Receptor Downregulation:

Prolonged agonist exposure causes receptor internalization and reduced sensitivity:

• Beta-adrenergic receptors: Catecholamine infusions (dobutamine, isoprenaline) cause downregulation within 24-48 hours, reducing inotropic response [77]
• Opioid receptors: Continuous opioid infusions cause tolerance within 3-7 days, requiring dose escalation [78]

Tachyphylaxis:

Rapid onset of tolerance (minutes to hours):

• Nitrates: GTN tolerance develops within 12-24 hours due to oxidative stress and endothelial dysfunction [79]
• Vasopressin: Prolonged infusion causes V1 receptor desensitization [80]

Clinical Strategies:

• Drug holidays (discontinue nitrates for 8-12 hours overnight)
• Rotate drug classes (switch from morphine to fentanyl)
• Upregulate receptors (beta-blocker withdrawal causes receptor upregulation) [81]

4. Therapeutic Index

Therapeutic Index (TI):

TI = \frac{TD50}{ED50}

Where:

• TD₅₀: Dose producing toxicity in 50% of patients
• ED₅₀: Dose producing therapeutic effect in 50% of patients

Narrow Therapeutic Index (NTI) Drugs:

Drugs with TI below 2 require therapeutic drug monitoring (TDM) to avoid toxicity:

---

Loading Dose and Maintenance Dose Calculations

Loading Dose

The loading dose rapidly achieves therapeutic concentrations and depends on volume of distribution (Vd) and target concentration.

Formula:

Loading Dose (mg) = Vd × Ctarget × Weight (kg)

Example 1: Vancomycin in Septic Shock

• Patient: 80 kg, septic shock with capillary leak
• Vd (normal): 0.5 L/kg → Vd (sepsis): 0.8-1.0 L/kg (increased due to fluid resuscitation and third-spacing) [25]
• Target concentration: 20-25 mg/L
• Loading dose: 1.0 L/kg × 20 mg/L × 80 kg = 1,600 mg (or 20 mg/kg = 1,600 mg)

Standard loading dose: 25-30 mg/kg in sepsis (higher than 15-20 mg/kg in non-critically ill) [18]

Example 2: Amiodarone for Ventricular Tachycardia

• Patient: 70 kg
• Vd: 60 L/kg (highly lipophilic, large Vd) [84]
• Target concentration: 1-2.5 mg/L
• Loading dose: 150-300 mg IV over 10 minutes, followed by 1 mg/min infusion for 6 hours, then 0.5 mg/min [85]

Maintenance Dose

The maintenance dose replaces drug eliminated per dosing interval and depends on clearance (CL) and target concentration.

Formula:

Maintenance Dose Rate (mg/h) = CL × Ctarget

Or for intermittent dosing:

Maintenance Dose (mg) = \frac{CL × Ctarget × \tau}{F}

Where:

• CL: Clearance (L/h)
• Ctarget: Target concentration (mg/L)
• τ: Dosing interval (hours)
• F: Bioavailability (1.0 for IV)

Example 1: Vancomycin Maintenance Dosing with AUC Targeting

• Patient: 70 kg, CrCl 80 mL/min (normal renal function)
• Vancomycin clearance: ~5 L/h (0.07 L/h/kg × 70 kg) [18]
• Target AUC₀₋₂₄: 400-600 mg·h/L
• Target Cavg: AUC₀₋₂₄ / 24 = 500 / 24 = 20.8 mg/L
• Maintenance dose rate: 5 L/h × 20.8 mg/L = 104 mg/h = 2,500 mg/24h (or 15-20 mg/kg q12h)

Example 2: Piperacillin-Tazobactam Continuous Infusion

• Patient: 80 kg, ARC (CrCl 150 mL/min)
• Target concentration: 64 mg/L (4× MIC for Pseudomonas) [86]
• Clearance (ARC): ~15 L/h (increased from 10 L/h baseline)
• Maintenance rate: 15 L/h × 64 mg/L = 960 mg/h = 23 g/24h
• Standard dose: 16-18 g/24h continuous infusion (may be inadequate in ARC) [41]

Half-Life and Steady State

Half-Life (t₁/₂):

t1/2 = (0.693 × Vd)/(CL)

• Time for plasma concentration to decrease by 50%
• Determines time to steady state (4-5 half-lives) [87]

Steady State:

• Achieved after 4-5 half-lives of continuous dosing
• Drug input = drug elimination
• For vancomycin (t₁/₂ = 6-8 hours): steady state at 24-40 hours [18]
• For amiodarone (t₁/₂ = 40-60 days): steady state at 5-8 months [84]

Clinical Implication:

• Drugs with long half-lives (amiodarone, digoxin) require loading doses to achieve rapid therapeutic effect [88]
• Drugs with short half-lives (propofol, remifentanil) rapidly reach steady state but also rapidly offset [89]

---

Alterations in Specific Patient Populations

1. Sepsis and Septic Shock

Pathophysiological Changes:

Dosing Strategies in Sepsis:

• Beta-lactams: Higher loading doses (2 g piperacillin-tazobactam), extended/continuous infusion [91]
• Vancomycin: Loading dose 25-30 mg/kg, AUC-guided maintenance [18]
• Aminoglycosides: Higher loading dose (7-8 mg/kg), extended interval (q24-48h) [92]

2. Obesity (BMI ≥30 kg/m²)

Weight Descriptors for Dosing:

• Total Body Weight (TBW): Actual body weight
• Ideal Body Weight (IBW): IBW (male) = 50 kg + 2.3 kg per inch greater than 5 feet; IBW (female) = 45.5 kg + 2.3 kg per inch greater than 5 feet
• Adjusted Body Weight (AdjBW): AdjBW = IBW + 0.4 × (TBW - IBW)
• Lean Body Weight (LBW): Janmahasatian equation (accounts for height, weight, sex) [93]

Drug Dosing in Obesity:

Propofol Infusion Syndrome (PRIS) Prevention:

• Limit propofol to below 4 mg/kg/hr (based on TBW)
• Avoid infusions greater than 48-72 hours
• Monitor triglycerides q12-24h (stop if greater than 4-5 mmol/L)
• Monitor creatine kinase, lactate, ECG (Brugada pattern, arrhythmias) [16]

3. Elderly (≥65 Years)

Pharmacokinetic Changes:

• Reduced muscle mass: Lower Vd for hydrophilic drugs [99]
• Reduced renal function: GFR declines 1 mL/min/year after age 30; many elderly have CrCl below 60 mL/min despite "normal" serum creatinine [100]
• Reduced hepatic metabolism: Decreased hepatic blood flow and CYP450 activity [101]
• Increased body fat: Increased Vd for lipophilic drugs (benzodiazepines, propofol) [102]

Pharmacodynamic Changes:

• Increased CNS sensitivity: Benzodiazepines, opioids cause delirium at lower doses [103]
• Reduced baroreceptor sensitivity: Increased orthostatic hypotension risk with vasodilators [104]

Dosing Adjustments:

• Benzodiazepines: Reduce dose 25-50%, prefer short-acting agents (lorazepam, oxazepam) [105]
• Opioids: Reduce initial dose 25-50%, titrate slowly [106]
• Antibiotics: Adjust for reduced CrCl (use Cockcroft-Gault with actual body weight) [107]

4. Pregnancy

Pharmacokinetic Changes:

Dosing Adjustments in Pregnancy:

• Antibiotics: Increase dose or frequency (beta-lactams, aminoglycosides) [113]
• Anticonvulsants: Monitor free phenytoin levels; increase lamotrigine dose 2-3× [114]
• Enoxaparin: Increase dose in 3rd trimester; monitor anti-Xa levels [115]

Teratogenicity Risk:

• Category X (contraindicated): Warfarin, ACE inhibitors, statins
• Avoid if possible: Benzodiazepines (cleft palate risk), aminoglycosides (ototoxicity)
• Safer alternatives: Penicillins, cephalosporins (Category B) [116]

---

Therapeutic Drug Monitoring (TDM)

TDM is essential for drugs with narrow therapeutic index, high inter-patient PK variability, or critical clinical outcomes.

Indications for TDM

1. Narrow therapeutic index (digoxin, phenytoin, lithium)
2. High PK variability in critical illness (vancomycin, aminoglycosides)
3. Risk of toxicity with standard dosing (vancomycin nephrotoxicity, aminoglycoside ototoxicity)
4. Treatment failure on standard dosing (subtherapeutic antibiotics in ARC)
5. Unpredictable metabolism (phenytoin saturable kinetics, genetic polymorphisms) [117]

Common TDM Drugs in ICU

1. Vancomycin:

• Target: AUC₀₋₂₄ 400-600 mg·h/L (trough-based dosing is obsolete) [18]
• Calculation: Bayesian software (first-order PK equations) or 2-level measurement (peak and trough)
• Sampling: Trough pre-dose + random level 1-2 hours after end of infusion
• Nephrotoxicity risk: AUC₀₋₂₄ greater than 600 mg·h/L associated with 3-4× increased V-AKI [17]

2. Aminoglycosides (Gentamicin, Tobramycin, Amikacin):

• Target (extended interval): Peak 20-30 mg/L (gentamicin), trough below 1 mg/L [60]
• Concentration-dependent killing: Maximize Cmax/MIC greater than 8-10 [71]
• Sampling: Random level 6-14 hours post-dose, use Hartford nomogram or Bayesian software [118]
• Toxicity monitoring: Trough greater than 2 mg/L increases nephrotoxicity/ototoxicity risk [119]

3. Phenytoin:

• Target: Total 10-20 mg/L; free 1-2 mg/L [26]
• Hypoalbuminemia: Measure free phenytoin (therapeutic total may cause toxicity)
• Saturable kinetics: Michaelis-Menten elimination; small dose changes cause large concentration changes [120]

4. Digoxin:

• Target: 0.8-2.0 ng/mL (heart failure); 0.5-1.0 ng/mL preferred (lower mortality risk) [121]
• Sampling: Trough pre-dose (≥6 hours post-dose to allow distribution)
• Toxicity: Arrhythmias, AV block, nausea; exacerbated by hypokalaemia, hypomagnesemia [82]

Bayesian Dosing Software

Bayesian software uses population PK models and patient-specific data (age, weight, CrCl, measured levels) to predict optimal dosing:

• DoseMeRx, InsightRX, MwPharm
• Improves target attainment by 20-40% compared to empiric dosing [122]
• Particularly useful in complex patients (obesity, ARC, CRRT, pregnancy) [123]

---

Clinical Application: Antibiotic PK/PD Optimization

Beta-Lactams (Piperacillin-Tazobactam, Meropenem, Cefepime)

PK/PD Principle: Time-dependent killing; target %T>MIC 40-70% [70,74]

Standard Dosing Failures:

• DALI Study (2011): 16% of ICU patients achieved target beta-lactam concentrations with standard dosing [14]
• Subtherapeutic in ARC: 50-80% of patients with CrCl greater than 130 mL/min have %T>MIC below 50% [41]

Optimization Strategies:

1. Extended infusion: Infuse over 3-4 hours instead of 30 minutes

   • Meropenem 1 g over 3 hours q8h improves %T>MIC from 40% to 80% [124]
   • Piperacillin-tazobactam 4.5 g over 4 hours q8h vs 30-minute infusion [125]

2. Continuous infusion:

   • Meropenem 3-6 g/24h continuous infusion after 2 g loading dose [126]
   • Piperacillin-tazobactam 16-18 g/24h continuous infusion after 4.5 g loading [127]

3. Therapeutic drug monitoring (TDM):

   • Target concentration: 4-8× MIC for bactericidal effect [128]
   • For Pseudomonas (MIC 16 mg/L), target piperacillin 64-128 mg/L [86]

Evidence:

• MERCY Trial (2020): Continuous infusion meropenem reduced mortality vs intermittent infusion (HR 0.52, 95% CI 0.30-0.90) [129]
• BLING III Trial (2021): Continuous infusion beta-lactams showed trend toward reduced mortality (not statistically significant) [130]

Vancomycin

PK/PD Principle: AUC/MIC-dependent; target AUC₀₋₂₄/MIC greater than 400 [18,76]

AUC-Guided Dosing (2020 Guidelines):

• Target: AUC₀₋₂₄ 400-600 mg·h/L (assumes MIC ≤1 mg/L)
• Calculation: Bayesian software or 2-level method (peak + trough)
• Advantage: Reduces nephrotoxicity by 30-50% vs trough-based dosing [131]

Dosing Example:

• Loading dose: 25-30 mg/kg (sepsis, increased Vd)
• Maintenance: 15-20 mg/kg q8-12h (adjust based on CrCl)
• Monitor AUC₀₋₂₄ at 24-48 hours and adjust [18]

V-AKI Prevention:

• Avoid AUC₀₋₂₄ greater than 600 mg·h/L (3-4× increased nephrotoxicity risk) [17]
• Avoid concomitant nephrotoxins (aminoglycosides, NSAIDs, contrast)
• Monitor serum creatinine daily [132]

Aminoglycosides

PK/PD Principle: Concentration-dependent killing; target Cmax/MIC greater than 8-10 [71,72]

Extended Interval Dosing (EID):

• Dose: 5-7 mg/kg q24-48h (based on CrCl and measured levels)
• Advantages: Maximizes Cmax, reduces toxicity vs multiple daily dosing [133]
• Hartford Nomogram: Predicts interval based on random level 6-14 hours post-dose [118]

Toxicity Minimization:

• Target trough below 1 mg/L (nephrotoxicity/ototoxicity if greater than 2 mg/L) [119]
• Limit duration to 3-5 days (synergy with beta-lactams)
• Avoid concurrent nephrotoxins [134]

---

CICM Fellowship Exam Preparation

High-Yield PK/PD Concepts for CICM

Written Exam Focus:

1. Vd changes in sepsis/fluid overload (loading dose calculations)
2. ARC pathophysiology and antibiotic dosing (beta-lactams, vancomycin)
3. Protein binding alterations (hypoalbuminemia, free drug fraction)
4. Loading vs maintenance dose formulas (Vd, CL, target concentration)
5. Time-dependent vs concentration-dependent killing (beta-lactams vs aminoglycosides)
6. TDM targets (vancomycin AUC, aminoglycoside peak/trough, phenytoin free level)
7. CRRT drug removal (protein binding, Vd, sieving coefficient)
8. Propofol infusion syndrome (risk factors, monitoring, prevention)

Viva Exam Focus:

• Systematic approach to drug dosing in complex patients
• Interpretation of TDM results and dose adjustment
• Recognition of altered PK/PD in sepsis, ARC, obesity, organ failure
• Antibiotic optimization strategies (extended/continuous infusion)
• Patient safety (toxicity prevention, therapeutic drug monitoring)

---

SAQ Practice Questions

SAQ 1: Pharmacokinetic Principles in Septic Shock (15 Marks)

Clinical Scenario:

A 65-year-old man (80 kg, height 175 cm) is admitted to ICU with septic shock secondary to intra-abdominal sepsis. He has received 4 litres of crystalloid and is on norepinephrine 0.3 mcg/kg/min. His serum creatinine is 90 μmol/L, albumin 18 g/L. You prescribe piperacillin-tazobactam and vancomycin.

Questions:

a) Explain the pharmacokinetic changes in septic shock that affect antibiotic dosing. (6 marks)

b) Calculate the loading dose of vancomycin and justify your choice. (4 marks)

c) Describe the dosing strategy for piperacillin-tazobactam in this patient and explain the pharmacodynamic rationale. (5 marks)

---

Model Answer: SAQ 1

a) Pharmacokinetic changes in septic shock (6 marks):

Volume of Distribution (Vd) - Increased 2-3× for hydrophilic drugs: [1 mark]

• Capillary leak syndrome increases vascular permeability, causing fluid shift to extravascular space [10,11]
• Aggressive fluid resuscitation (4 L crystalloid) expands total body water by 30-50% [135]
• Third-spacing in peritoneum, pleura, and interstitial tissues increases Vd for hydrophilic antibiotics (beta-lactams, vancomycin, aminoglycosides) [24,25]
• Clinical impact: Higher loading doses required to achieve therapeutic concentrations [29]

Protein Binding - Decreased: [1 mark]

• Hypoalbuminemia (18 g/L, normal 35-50 g/L) reduces binding sites for acidic drugs [8,9]
• For highly protein-bound drugs (ceftriaxone 85-95% bound), free fraction increases from 10% to 20-30% [53]
• Increased free drug available for distribution and elimination; may require dose reduction for narrow therapeutic index drugs [50]

Renal Clearance - Variable (ARC or AKI): [2 marks]

• Augmented renal clearance (ARC): Occurs in 20-65% of septic shock patients with hyperdynamic circulation, fluid resuscitation, young age, and vasopressor use [6,7]

  • Defined as CrCl greater than 130 mL/min/1.73 m²
  • Causes subtherapeutic antibiotic levels in 50-80% of patients receiving standard dosing [41]
  • Requires higher doses or extended/continuous infusion [44]

• Acute kidney injury (AKI): Occurs in 40-50% of septic shock (KDIGO Stage 2-3) [136]

  • Reduces renal clearance, causing drug accumulation
  • Requires dose reduction or interval extension [39]

Hepatic Clearance - Decreased: [1 mark]

• Hepatic hypoperfusion (splanchnic vasoconstriction, reduced cardiac output) reduces hepatic blood flow by 30-50% [30]
• Inflammatory cytokines (IL-6, TNF-α) downregulate CYP450 enzyme expression by 20-60% [31]
• Prolongs half-life of hepatically metabolized drugs (midazolam, fentanyl, propofol) [33]

Clinical Implication: [1 mark]

• Empiric dosing fails in 30-60% of critically ill patients; therapeutic drug monitoring (TDM) and Bayesian dosing software improve target attainment [13,14,122]

---

b) Vancomycin loading dose calculation and justification (4 marks):

Normal Vancomycin PK: [0.5 marks]

• Vd (healthy): 0.5 L/kg
• Vd (septic shock): 0.8-1.0 L/kg (increased due to capillary leak and fluid resuscitation) [25]

Loading Dose Formula: [1 mark]

Loading Dose = Vd × Ctarget × Weight

Calculation: [1.5 marks]

• Vd in sepsis: 1.0 L/kg (increased from 0.5 L/kg)
• Target concentration: 20-25 mg/L (recommended for serious infections) [18]
• Weight: 80 kg
• Loading dose: 1.0 L/kg × 20 mg/L × 80 kg = 1,600 mg (or 20 mg/kg)

Alternatively, use 25-30 mg/kg loading dose guideline: 25 mg/kg × 80 kg = 2,000 mg [18]

Justification: [1 mark]

• Higher loading dose (25-30 mg/kg) is required in sepsis compared to non-critically ill patients (15-20 mg/kg) due to increased Vd [18]
• Loading dose is independent of renal function (depends only on Vd and target concentration) [87]
• Achieves rapid therapeutic concentrations (target AUC₀₋₂₄ 400-600 mg·h/L) within first dosing interval [18]

Maintenance Dosing: [Not asked, but relevant]

• Depends on renal function (CrCl); typical dose 15-20 mg/kg q8-12h
• Monitor AUC₀₋₂₄ at 24-48 hours using Bayesian software or 2-level method
• Avoid AUC₀₋₂₄ greater than 600 mg·h/L (increased nephrotoxicity risk) [17]

---

c) Piperacillin-tazobactam dosing strategy and pharmacodynamic rationale (5 marks):

Pharmacodynamic Principle: [1 mark]

• Piperacillin is a time-dependent beta-lactam antibiotic [70,74]
• Bactericidal activity depends on time above MIC (%T>MIC), not peak concentration [75]
• Target %T>MIC: greater than 50% for bacteriostatic, greater than 70% for bactericidal effect against Gram-negative organisms [75]

Standard Dosing Inadequacy: [1 mark]

• DALI Study (2011): Only 16% of ICU patients achieved target beta-lactam concentrations with standard intermittent dosing (4.5 g q6-8h over 30 minutes) [14]
• Subtherapeutic in sepsis due to:
  • Increased Vd (2-3×) lowers peak concentration [24]
  • Augmented renal clearance (ARC) increases elimination [41]
  • High MIC targets for resistant organisms (Pseudomonas, ESBL) [86]

Recommended Dosing Strategy: [2 marks]

Option 1: Extended Infusion

• Dose: 4.5 g over 3-4 hours q6-8h (total 13.5-18 g/day)
• Rationale: Prolongs infusion time to maintain plasma concentration above MIC for 70-100% of dosing interval [125]
• Evidence: Extended infusion improves %T>MIC from 40-50% to 80-90% vs 30-minute infusion [137]

Option 2: Continuous Infusion (Preferred in Severe Sepsis/ARC)

• Loading dose: 4.5 g IV over 30 minutes
• Maintenance: 16-18 g/24h continuous infusion (or up to 24 g/24h in ARC)
• Rationale: Maintains constant plasma concentration above MIC throughout entire 24-hour period [127]
• Evidence:
  • "BLING III Trial (2021): Continuous infusion showed trend toward reduced 90-day mortality (OR 0.84, p=0.06) [130]"
  • "Meta-analysis (2018): Continuous infusion associated with lower mortality (OR 0.64, 95% CI 0.48-0.84) in severe infections [138]"

Therapeutic Drug Monitoring (TDM): [1 mark]

• Target concentration: 4-8× MIC for bactericidal effect [128]
• For Pseudomonas (MIC 16 mg/L), target piperacillin concentration: 64-128 mg/L [86]
• Measure steady-state concentration at 24-48 hours and adjust infusion rate
• TDM particularly important in:
  • ARC (CrCl greater than 130 mL/min) - 50-80% fail to achieve target [41]
  • Obesity (BMI greater than 30 kg/m²) - increased Vd [139]
  • CRRT - variable drug removal [48]

Additional Considerations:

• Monitor for toxicity: Neurotoxicity (seizures) at concentrations greater than 400 mg/L, especially with renal impairment [140]
• Compatibility: Piperacillin-tazobactam stable in 0.9% saline or dextrose for continuous infusion (protect from light) [127]

---

SAQ 2: Therapeutic Drug Monitoring and Dose Adjustment (15 Marks)

Clinical Scenario:

A 45-year-old woman (60 kg, BMI 22 kg/m²) with community-acquired pneumonia is admitted to ICU with respiratory failure and AKI (serum creatinine 250 μmol/L, baseline 70 μmol/L). She is intubated and receiving vancomycin for suspected MRSA pneumonia. Her initial vancomycin dose was 1 g q12h.

Day 3 TDM results:

• Vancomycin trough (pre-dose): 28 mg/L
• Estimated AUC₀₋₂₄: 750 mg·h/L
• Albumin: 22 g/L

Questions:

a) Interpret the vancomycin therapeutic drug monitoring results. What are the risks? (5 marks)

b) Calculate the appropriate dose adjustment to achieve target AUC₀₋₂₄ 400-600 mg·h/L. (5 marks)

c) Discuss the principles of therapeutic drug monitoring for narrow therapeutic index drugs in ICU. (5 marks)

---

Model Answer: SAQ 2

a) Interpretation of vancomycin TDM results and risks (5 marks):

TDM Result Interpretation: [2 marks]

• Trough concentration: 28 mg/L - Supratherapeutic [0.5 marks]

  • "Target trough (outdated): 15-20 mg/L for serious infections [18]"
  • "Current recommendation: Trough-based dosing is obsolete; use AUC₀₋₂₄ targeting instead [18]"

• AUC₀₋₂₄: 750 mg·h/L - Significantly elevated [0.5 marks]

  • "Target AUC₀₋₂₄: 400-600 mg·h/L (2020 guidelines) [18]"
  • Actual AUC₀₋₂₄ 750 mg·h/L is 25-88% above target range

• Cause of supratherapeutic level: [1 mark]

  • "Acute kidney injury (AKI): Creatinine 250 μmol/L (baseline 70 μmol/L) represents severe AKI (KDIGO Stage 3) [136]"
  • Vancomycin is 90% renally excreted; reduced GFR prolongs half-life from 6-8 hours to 24-48 hours in AKI [39]
  • Initial dosing (1 g q12h) was not adjusted for renal impairment, causing accumulation [18]

Risks of Supratherapeutic Vancomycin: [3 marks]

1. Vancomycin-Associated Acute Kidney Injury (V-AKI): [1.5 marks]

• Definition: Increase in serum creatinine ≥0.5 mg/dL or ≥50% from baseline attributable to vancomycin [17]
• Incidence: 5-35% in ICU patients; increases 3-4× with AUC₀₋₂₄ greater than 600 mg·h/L [17,18]
• Mechanism: Oxidative stress, proximal tubular cell injury, interstitial nephritis [132]
• Risk factors (present in this patient):
  • "AUC₀₋₂₄ greater than 600 mg·h/L (this patient: 750 mg·h/L) [17]"
  • Pre-existing AKI (creatinine 250 μmol/L) [132]
  • Hypoalbuminemia (22 g/L) - increased free drug fraction [8]
  • Concurrent nephrotoxins (contrast, NSAIDs, aminoglycosides) [132]

2. Ototoxicity: [0.5 marks]

• Irreversible cochlear damage (high-frequency hearing loss, tinnitus) [141]
• Risk increases with trough greater than 20 mg/L, duration greater than 7 days, concurrent aminoglycosides [141]

3. Red Man Syndrome (Infusion-Related Reaction): [0.5 marks]

• Histamine-mediated flushing, pruritus, hypotension [142]
• Risk increases with rapid infusion or high peak concentrations
• Not directly related to AUC/trough, but exacerbated by supratherapeutic dosing

4. Therapeutic Failure (Paradoxical): [0.5 marks]

• While high AUC suggests adequate exposure, excessive nephrotoxicity may necessitate drug discontinuation, leading to treatment failure [18]
• Balance between efficacy (AUC₀₋₂₄/MIC greater than 400) and safety (AUC₀₋₂₄ below 600 mg·h/L) is narrow [76]

Immediate Actions: [Not asked, but clinically essential]

• Hold vancomycin until AUC₀₋₂₄ falls to target range (400-600 mg·h/L)
• Monitor serum creatinine daily, urinalysis for casts/proteinuria
• Recalculate dosing based on current renal function (likely q24-48h dosing or dose reduction)
• Consider alternative anti-MRSA agent if nephrotoxicity worsens (linezolid, daptomycin) [143]

---

b) Vancomycin dose adjustment to achieve target AUC₀₋₂₄ 400-600 mg·h/L (5 marks):

Step 1: Estimate Current Clearance (CL): [1.5 marks]

Using steady-state AUC₀₋₂₄:

CL = (Daily Dose)/(AUC0-24)

• Current daily dose: 1 g q12h = 2,000 mg/24h
• Current AUC₀₋₂₄: 750 mg·h/L
• CL = 2,000 mg / 750 mg·h/L = 2.67 L/h [1 mark]

(Normal vancomycin clearance: ~5 L/h for 60 kg patient; this patient's CL is halved due to AKI) [18]

Step 2: Calculate New Daily Dose for Target AUC₀₋₂₄: [1.5 marks]

New Daily Dose = CL × Target AUC0-24

• Target AUC₀₋₂₄: 400-600 mg·h/L (use midpoint 500 mg·h/L)
• CL: 2.67 L/h
• New daily dose: 2.67 L/h × 500 mg·h/L = 1,335 mg/24h [1 mark]

Step 3: Practical Dosing Regimen: [1.5 marks]

Option 1: Intermittent Dosing

• Dose: 750 mg q24h (or 1 g q24h, monitoring AUC₀₋₂₄) [0.5 marks]
• Rationale: AKI prolongs half-life; q24h dosing avoids accumulation

Option 2: Extended Interval with Weight-Based Dosing

• Dose: 15 mg/kg q24-48h (15 mg/kg × 60 kg = 900 mg) [0.5 marks]
• Adjust interval based on renal function:
  • "CrCl 10-25 mL/min: q24-48h [18]"
  • Monitor vancomycin levels before 3rd dose and adjust [18]

Monitoring Plan: [0.5 marks]

• Hold current dose until AUC₀₋₂₄ below 600 mg·h/L (estimate washout period: 2-3 half-lives = 48-72 hours in AKI)
• Restart at 750 mg q24h
• Measure trough + random level at 24-48 hours post-restart
• Recalculate AUC₀₋₂₄ using Bayesian software (DoseMeRx, InsightRX) [122]
• Adjust to achieve AUC₀₋₂₄ 400-600 mg·h/L

Additional Considerations: [0.5 marks]

• Monitor serum creatinine daily; discontinue vancomycin if AKI worsens (consider linezolid switch) [143]
• Avoid nephrotoxin co-administration (NSAIDs, aminoglycosides, contrast)
• Duration: Reassess need for vancomycin daily; typical pneumonia course 7-10 days [18]

---

c) Principles of therapeutic drug monitoring (TDM) for narrow therapeutic index drugs in ICU (5 marks):

Definition of Narrow Therapeutic Index (NTI): [0.5 marks]

• Drugs with therapeutic index (TI) below 2, where TI = TD₅₀ / ED₅₀ [87]
• Small difference between therapeutic and toxic concentrations
• Examples: Vancomycin, aminoglycosides, digoxin, phenytoin, lithium, theophylline [117]

Indications for TDM in ICU: [1.5 marks]

1. Narrow therapeutic index with risk of toxicity (vancomycin nephrotoxicity, aminoglycoside ototoxicity) [117]
2. High inter-patient PK variability due to critical illness (altered Vd, clearance, protein binding) [2,3]
3. Treatment failure on standard dosing (subtherapeutic antibiotics in ARC, enzyme inducers/inhibitors) [13,44]
4. Unpredictable metabolism (phenytoin saturable kinetics, CYP450 genetic polymorphisms) [120]
5. Drug interactions (warfarin, digoxin, anticonvulsants) [144]

Key Principles of TDM: [3 marks]

1. Sampling Timing: [1 mark]

• Trough (pre-dose): Minimum concentration before next dose (vancomycin, digoxin, phenytoin)

  • Reflects drug elimination and guides interval adjustment [18]
  • Must be drawn within 30 minutes before next dose (not early)

• Peak (post-dose): Maximum concentration after administration (aminoglycosides)

  • "For aminoglycosides: 30-60 minutes post-infusion (assess Cmax/MIC) [60]"
  • "Caution: Measure after distribution phase (avoid sampling during infusion or immediate post-infusion)"

• Steady-state: After 4-5 half-lives of continuous dosing [87]

  • "Vancomycin: 24-48 hours (normal t₁/₂ 6-8 hours)"
  • "Digoxin: 5-7 days (t₁/₂ 36 hours)"
  • "Phenytoin: 5-10 days (t₁/₂ 12-24 hours, longer in saturation)"

• Random level + trough (2-level method): For AUC₀₋₂₄ calculation (vancomycin) [18]

2. Interpretation in Context: [1 mark]

• Total vs free drug concentration: For highly protein-bound drugs (greater than 80%), measure free (unbound) concentration in hypoalbuminemia [50,57]

  • "Phenytoin: Therapeutic total 10-20 mg/L assumes albumin 40 g/L; if albumin 20 g/L, free fraction doubles (measure free phenytoin) [26]"
  • "Valproate: Therapeutic total 50-100 mg/L; measure free valproate in hypoalbuminemia [52]"

• PK/PD targets: Align TDM with pharmacodynamic endpoint [70]

  • "Vancomycin: AUC₀₋₂₄/MIC greater than 400 (not trough alone) [18,76]"
  • "Aminoglycosides: Cmax/MIC greater than 8-10, trough below 1 mg/L [71,72]"
  • "Beta-lactams: %T>MIC greater than 70% (measure mid-dose concentration) [75]"

3. Dose Adjustment Using Pharmacokinetic Equations: [0.5 marks]

• Linear (first-order) kinetics: Dose adjustment proportional to concentration change [87]

  • "Example: If vancomycin AUC₀₋₂₄ is 750 mg·h/L and target is 500 mg·h/L, reduce dose by (500/750) = 67%"

• Non-linear (saturable) kinetics: Small dose changes cause large concentration changes [120]

  • "Example: Phenytoin exhibits Michaelis-Menten kinetics; dose increments should be 25-50 mg (not 100 mg) to avoid toxicity"

• Bayesian software: Integrates population PK models with patient-specific data (age, weight, CrCl, measured levels) for individualized dosing [122,123]

  • Improves target attainment by 20-40% vs empiric dosing [122]
  • Essential for complex patients (obesity, ARC, CRRT, pregnancy)

4. Monitoring for Toxicity: [0.5 marks]

• Clinical monitoring: Signs/symptoms of toxicity (nephrotoxicity, ototoxicity, neurotoxicity, arrhythmias) [141]
• Laboratory monitoring:
  • "Vancomycin: Serum creatinine daily, urinalysis (casts, proteinuria) [132]"
  • "Aminoglycosides: Creatinine, audiometry (high-risk patients) [119]"
  • "Digoxin: Potassium, magnesium, ECG (arrhythmias with hypokalaemia) [82]"
• Threshold for discontinuation: If toxicity outweighs benefit, switch to alternative agent [143]

5. Special Populations Requiring Intensive TDM: [Not asked, but relevant]

• Obesity: Altered Vd (lipophilic drugs), increased clearance (renal, hepatic) [28,93]
• ARC: Increased clearance causes subtherapeutic levels despite standard dosing [6,7]
• CRRT: Variable drug removal; adjust for effluent dose, protein binding, Vd [40,46]
• Pregnancy: Increased Vd, GFR, hepatic metabolism; requires dose escalation [108-110]

---

Viva Scenarios

Viva Scenario 1: Comprehensive Pharmacokinetics in Critical Illness (20 Marks)

Scenario:

You are the ICU consultant. A 55-year-old man (90 kg, BMI 32 kg/m², height 170 cm) with obesity is admitted with severe community-acquired pneumonia complicated by septic shock. He has received 5 litres of crystalloid and is on norepinephrine 0.4 mcg/kg/min. His blood results show:

• Serum creatinine: 80 μmol/L (baseline 85 μmol/L)
• Albumin: 20 g/L
• Blood cultures: Pending

You plan to start empiric antibiotics (piperacillin-tazobactam and vancomycin) and consider sedation for intubation.

---

Examiner: "Can you explain the pharmacokinetic changes in septic shock that would affect antibiotic dosing in this patient?"

Candidate:

"Certainly. Septic shock causes profound alterations in all four phases of pharmacokinetics: absorption, distribution, metabolism, and excretion. The most clinically relevant changes for antibiotic dosing are in distribution and excretion.

Volume of Distribution (Vd):

Septic shock increases Vd for hydrophilic antibiotics like piperacillin-tazobactam and vancomycin by 2-3 times normal due to:

1. Capillary leak syndrome: Inflammatory cytokines (IL-1, IL-6, TNF-α) increase vascular permeability, causing fluid shift from intravascular to extravascular compartments. This is most pronounced in the first 48-72 hours of sepsis.

2. Aggressive fluid resuscitation: This patient has received 5 litres of crystalloid, expanding total body water by approximately 6-7 kg (assuming 0.9% saline distributes across extracellular fluid).

3. Third-spacing: Fluid accumulates in pleural, peritoneal, and interstitial spaces, creating a reservoir for hydrophilic drugs.

The clinical consequence is that higher loading doses are required to achieve therapeutic plasma concentrations. For example, vancomycin Vd increases from 0.5 L/kg to 0.8-1.0 L/kg in sepsis, necessitating loading doses of 25-30 mg/kg instead of the usual 15-20 mg/kg.

Renal Clearance:

Septic shock can cause either augmented renal clearance (ARC) or acute kidney injury (AKI), with opposite dosing implications.

In this patient, serum creatinine is 80 μmol/L (near baseline 85 μmol/L), suggesting preserved renal function. However, I would be concerned about ARC, which occurs in 20-65% of ICU patients, particularly those who are:

• Young (this patient is 55, moderate risk)
• Obese (BMI 32 kg/m², high risk)
• Hyperdynamic (on vasopressors, large fluid resuscitation)

ARC is defined as creatinine clearance greater than 130 mL/min/1.73 m² and results in:

• Increased elimination of renally excreted antibiotics (beta-lactams, vancomycin, aminoglycosides)
• Subtherapeutic plasma concentrations in 50-80% of patients receiving standard dosing
• Higher risk of treatment failure and antimicrobial resistance

I would measure 8-hour urine creatinine clearance to detect ARC, as serum creatinine underestimates GFR in this scenario.

Protein Binding:

This patient has hypoalbuminemia (albumin 20 g/L, normal 35-50 g/L), which affects highly protein-bound drugs. Piperacillin is 20-30% protein-bound (minimal impact), but ceftriaxone (85-95% bound) or ertapenem (85-95% bound) would have significantly increased free drug fractions. Vancomycin is 30-50% protein-bound, so the impact is moderate.

Increased free drug fraction leads to:

• Greater distribution into tissues (increased Vd)
• Increased renal clearance (more free drug filtered)
• Potentially lower total plasma concentrations despite adequate free (active) drug

Hepatic Metabolism:

Septic shock reduces hepatic drug metabolism by:

• Reduced hepatic blood flow (splanchnic vasoconstriction, norepinephrine use)
• Cytokine-mediated downregulation of CYP450 enzymes by 20-60%

This prolongs the half-life of hepatically metabolized sedatives (midazolam, propofol, fentanyl), increasing the risk of accumulation and prolonged sedation. However, piperacillin-tazobactam and vancomycin are predominantly renally excreted, so hepatic dysfunction has minimal impact."

---

Examiner: "How would you dose vancomycin in this patient? Walk me through your loading dose calculation."

Candidate:

"I would use a loading dose of 25-30 mg/kg based on total body weight to rapidly achieve therapeutic plasma concentrations. Let me calculate this step-by-step.

Loading Dose Formula:

Loading Dose = Vd × Ctarget × Weight

Step 1: Determine Volume of Distribution (Vd)

• Normal Vd for vancomycin: 0.5 L/kg
• Vd in septic shock with fluid resuscitation: 0.8-1.0 L/kg (I'll use 1.0 L/kg to account for 5 L crystalloid and capillary leak)

Step 2: Determine Target Concentration (Ctarget)

• For serious MRSA infections (pneumonia), the target AUC₀₋₂₄ is 400-600 mg·h/L
• To estimate the loading dose, I'll target a peak concentration of 20-25 mg/L

Step 3: Determine Weight

• This patient weighs 90 kg (total body weight)
• For vancomycin, I use total body weight (TBW) for the loading dose, as Vd is increased in obesity

Step 4: Calculate Loading Dose

Loading Dose = 1.0 \, L/kg × 20 \, mg/L × 90 \, kg = 1,800 \, mg

Alternatively, using the 25-30 mg/kg guideline:

Loading Dose = 25 \, mg/kg × 90 \, kg = 2,250 \, mg

Recommended Dose: 2,000 mg IV over 1-2 hours (rounded from 2,250 mg)

Justification:

1. Independent of renal function: Loading dose depends only on Vd and target concentration, not clearance. Even if this patient develops AKI later, the loading dose remains 25-30 mg/kg.

2. Higher in obesity: Vancomycin distributes into lean body mass and extracellular fluid. In obesity, both are increased, so TBW-based dosing is appropriate for the loading dose.

3. Higher in sepsis: The 2-3× increase in Vd necessitates higher loading doses compared to non-critically ill patients.

Maintenance Dose:

For the maintenance dose, I would use:

• 15-20 mg/kg q8-12h based on adjusted body weight (AdjBW) and renal function
• AdjBW = IBW + 0.4 × (TBW - IBW)
  • IBW (male, 170 cm) ≈ 70 kg
  • AdjBW = 70 + 0.4 × (90 - 70) = 78 kg
• Maintenance dose: 15-20 mg/kg × 78 kg = 1,170-1,560 mg q12h (round to 1,500 mg q12h)

Monitoring:

• Measure vancomycin trough + random level at 24-48 hours (after 3rd or 4th dose at steady state)
• Calculate AUC₀₋₂₄ using Bayesian software (target 400-600 mg·h/L)
• Adjust maintenance dose to achieve target AUC
• Monitor for nephrotoxicity: Daily creatinine, urinalysis; avoid AUC₀₋₂₄ greater than 600 mg·h/L

If ARC is confirmed (CrCl greater than 130 mL/min), I may need to increase the maintenance dose to 20-25 mg/kg q8-12h or use continuous infusion."

---

Examiner: "You mentioned augmented renal clearance. How would you detect ARC, and how would it change your antibiotic dosing?"

Candidate:

"Augmented renal clearance (ARC) is a critically important but often under-recognized phenomenon in ICU patients. It is defined as creatinine clearance greater than 130 mL/min/1.73 m² and occurs in 20-65% of critically ill patients.

Detection of ARC:

1. Clinical Risk Factors:

ARC is more common in patients who are:

• Young (below 50 years) - This patient is 55, moderate risk
• Obese (BMI greater than 30 kg/m²) - This patient has BMI 32, high risk
• Trauma, burns, or sepsis - This patient has septic shock, high risk
• Receiving large-volume fluid resuscitation - This patient received 5 L, high risk
• On vasopressors with hyperdynamic circulation - This patient is on norepinephrine 0.4 mcg/kg/min, high risk

2. Serum Creatinine is Unreliable:

• Serum creatinine underestimates GFR in ARC due to:
  • Increased creatinine secretion by proximal tubular cells (overestimates GFR by 10-40%)
  • Hemodilution from fluid resuscitation (lowers creatinine concentration)
• This patient's creatinine is 80 μmol/L, which appears "normal," but could mask CrCl of 150-200 mL/min

3. Measured Urine Creatinine Clearance (Gold Standard):

• Perform 8-hour or 24-hour urine collection to calculate CrCl:

CrCl = \frac{UCr × V}{PCr × T}

Where:

• UCr = Urine creatinine concentration (μmol/L)

• V = Urine volume (mL)

• PCr = Plasma creatinine (μmol/L)

• T = Time (minutes)

• If CrCl greater than 130 mL/min/1.73 m², ARC is confirmed

Impact of ARC on Antibiotic Dosing:

ARC increases the elimination of renally excreted antibiotics, causing subtherapeutic concentrations in 50-80% of patients receiving standard dosing. The most affected antibiotics are:

1. Beta-Lactams (Piperacillin-Tazobactam, Meropenem, Cefepime):

• Hydrophilic, low protein binding (20-30%), predominantly renally excreted
• DALI Study (2011): Only 16% of ICU patients achieved target %T>MIC with standard dosing
• In ARC, clearance increases from 10 L/h to 15-20 L/h, reducing %T>MIC from 70% to 30-40%

Dosing Strategy:

• Standard dose: Piperacillin-tazobactam 4.5 g q6h (18 g/24h)
• ARC dose: 4.5 g q6h extended infusion over 3-4 hours, OR continuous infusion 16-24 g/24h after loading dose
• TDM: Measure piperacillin concentration, target 4-8× MIC (64-128 mg/L for Pseudomonas with MIC 16 mg/L)

2. Vancomycin:

• 90% renally excreted
• ARC increases clearance from 5 L/h to 8-12 L/h, causing trough levels below 10 mg/L in 60% of patients

Dosing Strategy:

• Standard dose: 15-20 mg/kg q12h
• ARC dose: 20-25 mg/kg q8-12h, OR continuous infusion 40-60 mg/kg/24h after loading dose
• TDM: Target AUC₀₋₂₄ 400-600 mg·h/L using Bayesian software; measure levels at 24-48h

3. Aminoglycosides (Gentamicin, Tobramycin):

• 95% renally excreted, concentration-dependent killing
• ARC reduces trough concentrations but also shortens half-life (advantageous for extended interval dosing)

Dosing Strategy:

• Standard dose: 5-7 mg/kg q24h
• ARC dose: 7-8 mg/kg q24h with closer monitoring (Hartford nomogram or Bayesian dosing)
• TDM: Measure random level at 6-14h post-dose, target trough below 1 mg/L to avoid nephrotoxicity

Monitoring for ARC:

• Repeat urine CrCl measurement every 2-3 days in high-risk patients (ARC is dynamic and resolves as sepsis improves)
• If ARC persists, continue high-dose or extended/continuous infusion strategies
• If CrCl normalizes (below 130 mL/min), de-escalate to standard dosing to avoid toxicity

Summary for This Patient:

Given this patient's obesity, septic shock, and large fluid resuscitation, I have a high clinical suspicion for ARC. I would:

1. Measure 8-hour urine CrCl immediately
2. Start piperacillin-tazobactam 4.5 g q6h extended infusion (3-4 hours) or continuous infusion 18-24 g/24h
3. Start vancomycin 2,000 mg loading dose, then 1,500 mg q12h with plan for AUC-guided dose adjustment
4. Consider Bayesian TDM software (DoseMeRx, InsightRX) for individualized dosing
5. Repeat CrCl measurement at 48-72 hours to reassess"

---

Examiner: "The patient deteriorates and requires intubation. You plan to use propofol for induction. How does obesity affect propofol dosing, and what are the risks?"

Candidate:

"Propofol is a highly lipophilic sedative-hypnotic agent with unique pharmacokinetic properties that are significantly altered in obesity. I need to carefully consider the dosing strategy to balance rapid onset of sedation with the risk of hemodynamic instability and propofol infusion syndrome (PRIS).

Pharmacokinetic Changes in Obesity:

1. Volume of Distribution (Vd):

• Propofol is highly lipophilic (97-99% protein-bound, log P 4.6)

• In obesity, Vd increases proportionally to total body weight (TBW) due to:

  • Increased adipose tissue mass (primary distribution compartment)
  • Increased lean body mass (muscle, organs)
  • Increased blood volume and extracellular fluid

• Vd (normal weight): 3-5 L/kg

• Vd (obesity): 5-8 L/kg (based on TBW)

2. Clearance (CL):

• Propofol has a high hepatic extraction ratio (0.7-0.9), so clearance depends on hepatic blood flow
• In obesity, hepatic blood flow and CYP2B6 activity increase, increasing clearance proportionally to TBW
• CL (normal weight): 25-35 mL/kg/min
• CL (obesity): 30-40 mL/kg/min (based on TBW)

3. Protein Binding:

• Propofol is 97-99% protein-bound (albumin and erythrocytes)
• In this patient with hypoalbuminemia (20 g/L), free fraction increases from 1-3% to 5-10%
• This increases the pharmacologically active free drug, raising the risk of hypotension and excessive sedation

Dosing Strategy for Propofol:

Induction Dose (Intubation):

• Use lean body weight (LBW) or adjusted body weight (AdjBW) to avoid overdosing

• LBW (Janmahasatian equation):

  • "Male: LBW = (9,270 × TBW) / (6,680 + 216 × BMI)"
  • "For this patient: LBW ≈ 70 kg"

• Recommended dose: 1.5-2.5 mg/kg LBW (or 1.0-1.5 mg/kg TBW)

  • "Using LBW 70 kg: 105-175 mg (round to 100-150 mg)"
  • "Using TBW 90 kg: 90-135 mg"

• Titrate slowly (10-20 mg boluses every 30-60 seconds) to avoid hypotension, especially in septic shock with preload-dependent hemodynamics

Maintenance Infusion:

• Use total body weight (TBW) for maintenance dosing, as clearance scales with TBW

• Recommended rate: 50-200 mcg/kg/min TBW, titrated to sedation target (RASS -2 to -4)

  • "For 90 kg: 4.5-18 mg/min = 270-1,080 mg/h"

• CRITICAL: Limit propofol to below 4 mg/kg/hr TBW to prevent PRIS

  • "For 90 kg: Maximum 360 mg/h (6 mg/min)"
  • 4 mg/kg/hr × 90 kg = 360 mg/h ceiling

Risks of Propofol in Obesity:

1. Propofol Infusion Syndrome (PRIS):

PRIS is a rare (1-5% incidence) but life-threatening complication with 18-48% mortality. It is characterized by:

• Metabolic acidosis (lactic acidosis due to mitochondrial dysfunction)
• Rhabdomyolysis (elevated CK, myoglobinuria)
• Cardiac dysfunction (Brugada-like ECG, arrhythmias, heart failure)
• Acute kidney injury (myoglobin-induced tubular necrosis)
• Hypertriglyceridemia (propofol is formulated in 10% lipid emulsion)

Risk Factors (This Patient Has Multiple):

• Obesity (BMI 32 kg/m²) - Increased risk due to higher cumulative dose if not capped
• High-dose propofol (greater than 4 mg/kg/hr for greater than 48-72 hours)
• Sepsis and critical illness (mitochondrial dysfunction, catabolamine use)
• Concurrent vasopressors (norepinephrine increases myocardial oxygen demand)
• Inadequate carbohydrate intake (fasting, reliance on fatty acid oxidation)

PRIS Prevention:

1. Dose capping: Limit to below 4 mg/kg/hr based on TBW (360 mg/h for this patient)
2. Duration limit: Avoid prolonged infusions greater than 48-72 hours (switch to midazolam or dexmedetomidine)
3. Monitor triglycerides q12-24h; stop propofol if greater than 4-5 mmol/L
4. Monitor CK, lactate, and ECG daily for PRIS signs (Brugada pattern, wide QRS, arrhythmias)
5. Provide adequate carbohydrate intake (enteral/parenteral nutrition) to reduce reliance on fat oxidation

2. Hemodynamic Instability:

• Propofol causes vasodilation (reduced SVR), myocardial depression (reduced contractility), and blunted sympathetic response
• In septic shock with norepinephrine 0.4 mcg/kg/min, this patient is at high risk for severe hypotension with induction

Mitigation Strategies:

• Preload optimization: Ensure adequate fluid resuscitation before induction (this patient received 5 L, likely adequate)
• Vasopressor optimization: Increase norepinephrine to 0.5-0.6 mcg/kg/min before induction to buffer propofol-induced hypotension
• Slow titration: Administer propofol in 10-20 mg boluses rather than rapid bolus
• Consider alternative agents: Ketamine 1-2 mg/kg IV (hemodynamically stable in shock) or etomidate 0.3 mg/kg IV (minimal cardiovascular effects)

3. Hypertriglyceridemia:

• Propofol is formulated in 10% lipid emulsion (1.1 kcal/mL)
• Prolonged infusion (greater than 48h) causes hypertriglyceridemia in 20-30% of patients
• In obesity, baseline triglycerides may already be elevated

Monitoring:

• Check triglycerides at baseline and q12-24h
• If triglycerides greater than 4-5 mmol/L, stop propofol and switch to alternative sedative (midazolam, dexmedetomidine)
• Account for propofol calories (360 mg/h = 36 mL/h lipid = 40 kcal/h) in nutrition plan

Preferred Sedation Strategy for This Patient:

Given obesity, septic shock, and PRIS risk, I would consider:

1. Induction: Ketamine 1-2 mg/kg IV (90-180 mg) - hemodynamically stable, no PRIS risk
2. Short-term sedation (below 24h): Propofol 50-100 mcg/kg/min (max 360 mg/h), titrated to RASS -2 to -4
3. Transition to midazolam or dexmedetomidine after 24-48h to avoid PRIS
4. Multimodal analgesia: Fentanyl or remifentanil infusion (opioid-sparing sedation)

Summary:

• Induction dose: 1.5-2.0 mg/kg LBW (100-150 mg), slow titration
• Maintenance: 50-200 mcg/kg/min TBW, maximum 4 mg/kg/hr (360 mg/h)
• Monitoring: Triglycerides, CK, lactate, ECG daily; stop if PRIS signs
• Duration limit: Transition to alternative sedative after 48-72h
• Hemodynamic support: Optimize preload and increase vasopressor before induction"

---

Examiner: "Thank you. That was comprehensive."

---

Viva Scenario 2: Drug Dosing in Renal Failure and CRRT (20 Marks)

Scenario:

A 70-year-old woman (65 kg) with chronic kidney disease (baseline creatinine 180 μmol/L) is admitted to ICU with urosepsis and acute-on-chronic kidney injury. Her current creatinine is 450 μmol/L. She is oliguric (below 100 mL urine/24h) despite fluid resuscitation. You plan to start continuous renal replacement therapy (CRRT) with continuous venovenous hemodiafiltration (CVVHDF) at 25 mL/kg/h effluent dose using regional citrate anticoagulation.

Blood cultures are positive for Escherichia coli (ESBL-producing, susceptible to meropenem, MIC 2 mg/L).

---

Examiner: "How does CRRT affect drug clearance, and how would you dose meropenem in this patient?"

Candidate:

"CRRT removes drugs from the circulation through three mechanisms: convection, diffusion, and adsorption. Understanding these mechanisms is essential to optimize antibiotic dosing and avoid subtherapeutic concentrations.

Mechanisms of Drug Clearance by CRRT:

1. Convection (Hemofiltration):

• Solute drag across the hemofilter membrane along with ultrafiltrate flow
• Depends on:
  • "Sieving coefficient (SC): The fraction of drug in plasma water that passes through the membrane"
    • SC ≈ 1 for small molecules (below 30 kDa) with low protein binding
    • SC ≈ 0 for highly protein-bound drugs (greater than 90%) or large molecules (greater than 50 kDa)
  • "Effluent flow rate: Higher effluent dose (mL/kg/h) increases drug removal"

2. Diffusion (Hemodialysis):

• Movement of drug across the membrane along a concentration gradient (blood to dialysate)
• Depends on:
  • "Molecular weight: Small molecules (below 500 Da) diffuse readily; large molecules (greater than 10 kDa) diffuse poorly"
  • "Concentration gradient: Fresh dialysate maintains maximal gradient"
  • "Dialysate flow rate: Higher flow increases diffusion clearance"

3. Adsorption:

• Drug binding to the CRRT membrane surface
• Minimal for most drugs; clinically significant for:
  • Cytokines (IL-6, TNF-α) - removed by high-flux membranes
  • Some antibiotics (vancomycin, aminoglycosides) - transient adsorption in first 24-48h, then saturates

Factors Predicting CRRT Drug Removal:

Meropenem Pharmacokinetic Properties:

• Molecular weight: 383 Da (small, readily removed)
• Protein binding: 2% (very low, SC ≈ 0.98)
• Vd: 0.2-0.3 L/kg (hydrophilic, small Vd)
• Renal excretion: 70-80% (remainder hepatic metabolism)

Conclusion: Meropenem is extensively removed by CRRT due to low protein binding, small molecular weight, and small Vd. Higher doses are required compared to standard dosing.

Dosing Meropenem in CVVHDF:

Step 1: Determine PK/PD Target

• Meropenem is a time-dependent beta-lactam; bactericidal activity depends on %T>MIC
• Target: %T>MIC ≥40% for bacteriostatic, ≥70% for bactericidal effect
• For ESBL E. coli with MIC 2 mg/L, I aim for 4-8× MIC plasma concentration (8-16 mg/L) to ensure %T>MIC greater than 70%

Step 2: Account for CRRT Clearance

• CRRT effluent dose: 25 mL/kg/h × 65 kg = 1,625 mL/h (1.625 L/h)

• Sieving coefficient for meropenem: 0.98 (assume ≈1.0 for simplicity)

• CRRT clearance of meropenem: SC × effluent dose = 1.0 × 1.625 L/h = 1.625 L/h

• Residual renal clearance: Negligible (oliguric, creatinine 450 μmol/L, KDIGO Stage 3 AKI)

• Total clearance: CRRT clearance + residual renal clearance ≈ 1.625 L/h

Step 3: Calculate Maintenance Dose

Using the formula:

Maintenance Dose Rate = CL × Ctarget

• CL: 1.625 L/h
• Ctarget: 16 mg/L (4× MIC, accounting for sepsis-induced increased Vd)
• Maintenance dose rate: 1.625 L/h × 16 mg/L = 26 mg/h = 624 mg/24h

This is significantly lower than standard dosing (1 g q8h = 3 g/24h), but incorrect because it doesn't account for:

1. Increased Vd in sepsis (2-3× normal)
2. Intermittent dosing pharmacokinetics (peak and trough variability)
3. Need for loading dose

Recommended Dosing Strategy (Evidence-Based):

Option 1: Intermittent Dosing with Extended Infusion

• Loading dose: 1 g IV over 30 minutes (to rapidly achieve therapeutic concentrations given increased Vd in sepsis)
• Maintenance dose: 1 g q8h IV over 3-4 hours (extended infusion to maximize %T>MIC)

Rationale:

• Standard CRRT dose for meropenem is 1 g q8-12h (3 g/24h)
• Extended infusion (3-4 hours) maintains plasma concentration greater than 4× MIC for 70-100% of the dosing interval
• Evidence: Studies show 1 g q8h achieves target %T>MIC in 80-90% of CRRT patients

Option 2: Continuous Infusion (Preferred)

• Loading dose: 2 g IV over 30 minutes
• Maintenance: 3-4 g/24h continuous infusion (125-167 mg/h)

Rationale:

• Maintains constant plasma concentration above MIC (target 8-16 mg/L)
• Maximizes %T>MIC (100% of 24 hours)
• Evidence: Continuous infusion meropenem associated with lower mortality vs intermittent dosing in severe sepsis (MERCY trial)

Step 4: Therapeutic Drug Monitoring (TDM)

• Measure meropenem steady-state concentration at 24-48 hours
• Target concentration: 4-8× MIC (8-16 mg/L for MIC 2 mg/L)
• Adjust infusion rate to achieve target
• Risk of neurotoxicity if concentration greater than 64 mg/L (especially with renal impairment)

Final Recommendation for This Patient:

• Loading dose: 2 g IV over 30 minutes
• Maintenance: 3 g/24h continuous infusion (after loading dose)
• TDM: Measure steady-state level at 24-48h, target 8-16 mg/L
• Monitor for neurotoxicity: Seizures, myoclonus, confusion (risk increases with concentrations greater than 64 mg/L and concurrent valproate, NSAIDs)

Additional Considerations:

1. If CRRT Effluent Dose Increases:

• Higher effluent doses (30-50 mL/kg/h) increase meropenem clearance proportionally
• At 50 mL/kg/h: Consider 4-6 g/24h continuous infusion or 1-2 g q6-8h intermittent

2. If CRRT is Discontinued:

• Anuric patient with CrCl below 10 mL/min: Reduce to 500 mg q12-24h (avoid accumulation and neurotoxicity)
• Meropenem half-life increases from 1 hour (normal) to 8-12 hours (anuric)

3. If Patient Recovers Renal Function:

• Measure CrCl; adjust dose based on renal function
• CrCl 26-50 mL/min: 1 g q12h
• CrCl 10-25 mL/min: 500 mg q12h
• CrCl below 10 mL/min: 500 mg q24h"

---

Examiner: "You mentioned regional citrate anticoagulation. How does citrate affect drug dosing and drug-drug interactions?"

Candidate:

"Regional citrate anticoagulation (RCA) is the preferred anticoagulation strategy for CRRT, as it reduces bleeding risk by 50% compared to systemic heparin. However, citrate has important pharmacokinetic and pharmacodynamic interactions that affect drug dosing and patient management.

Mechanism of Regional Citrate Anticoagulation:

• Citrate is infused into the CRRT circuit (pre-filter) at 3-4 mmol/L
• Citrate chelates ionized calcium (Ca²⁺), creating a local anticoagulant effect in the circuit (prevents clot formation)
• Calcium is removed in the ultrafiltrate, and calcium chloride is infused systemically (post-filter) to maintain normal serum ionized calcium (1.0-1.2 mmol/L)

Citrate Metabolism:

• Citrate is metabolized to bicarbonate in the liver (via Krebs cycle): 1 mmol citrate → 3 mmol bicarbonate
• Normal citrate clearance: 2-3 L/h (hepatic metabolism)
• In liver dysfunction, citrate accumulates, causing citrate toxicity

Citrate Toxicity:

Definition: Accumulation of citrate due to impaired hepatic metabolism (liver failure, shock, hypothermia)

Signs:

1. Hypocalcemia (ionized Ca²⁺ below 0.9 mmol/L despite calcium supplementation)
2. Elevated total calcium/ionized calcium ratio (Ca:iCa ratio): greater than 2.5 indicates citrate accumulation
3. Metabolic acidosis (paradoxical, despite citrate normally generating bicarbonate)
4. Hypernatremia (citrate solution contains sodium)
5. Prolonged QTc and arrhythmias (due to hypocalcemia)

Management:

• Reduce citrate infusion rate or switch to heparin anticoagulation
• Increase calcium replacement
• Optimize hepatic perfusion (vasopressors, inotropes)

Effect of Citrate on Drug Dosing and Interactions:

1. Calcium-Dependent Drugs:

Citrate-induced hypocalcemia affects drugs whose action depends on calcium:

• Calcium channel blockers (amlodipine, diltiazem, verapamil): Enhanced effect due to reduced ionized calcium; risk of bradycardia, hypotension
• Digoxin: Hypocalcemia increases digoxin binding to Na⁺/K⁺-ATPase, increasing toxicity (arrhythmias, AV block)
• Neuromuscular blockers (rocuronium, vecuronium): Hypocalcemia potentiates neuromuscular blockade, prolonging paralysis

Mitigation: Monitor ionized calcium q4-6h, maintain 1.0-1.2 mmol/L

2. Alkalosis and Protein Binding:

Citrate metabolism generates bicarbonate, causing metabolic alkalosis (pH 7.45-7.50, bicarbonate 28-32 mmol/L). Alkalosis affects drug protein binding:

• Alkalosis increases protein binding of acidic drugs (phenytoin, valproate), reducing free (active) fraction
• Alkalosis decreases ionization of weak bases (opioids, local anesthetics), increasing membrane permeability and CNS effects

Clinical Impact:

• Phenytoin: Total phenytoin level may be therapeutic, but free phenytoin is subtherapeutic; measure free phenytoin levels
• Opioids (morphine, fentanyl): Enhanced CNS penetration may increase sedation

3. Magnesium and Phosphate Depletion:

CRRT with citrate causes hypophosphatemia (80% incidence) and hypomagnesemia (40% incidence) due to:

• Chelation by citrate
• Removal in ultrafiltrate (phosphate MW 95 Da, magnesium MW 24 Da - both small, readily removed)

Clinical Impact:

• Hypomagnesemia potentiates digoxin toxicity, prolongs QTc, increases seizure risk with beta-lactams (meropenem, cefepime)
• Hypophosphatemia impairs respiratory muscle function (delayed weaning), reduces cardiac contractility, causes hemolysis

Mitigation:

• Supplement magnesium sulfate 2-4 g/24h IV and phosphate 20-40 mmol/24h IV
• Monitor daily; target Mg²⁺ greater than 0.8 mmol/L, PO₄³⁻ greater than 0.8 mmol/L

4. Drug-Drug Interactions via pH Alteration:

Citrate-induced alkalosis affects renal drug excretion:

• Weak acids (salicylates, methotrexate): Alkalosis promotes ionization, increasing renal excretion (lower plasma levels)
• Weak bases (amphetamines, quinidine): Alkalosis reduces ionization, decreasing renal excretion (higher plasma levels, risk of toxicity)

5. Sodium Load:

Citrate solutions (e.g., ACD-A, trisodium citrate) contain 130-150 mmol/L sodium. Citrate infusion at 3-4 mmol/L adds significant sodium load (200-300 mmol/24h).

Clinical Impact:

• Hypernatremia (serum Na⁺ 145-155 mmol/L) is common
• Exacerbates fluid overload (osmotic retention)
• May affect dosing of sodium-sensitive drugs (loop diuretics, hypertonic saline)

Monitoring for Citrate Anticoagulation:

To detect citrate toxicity and manage drug interactions, I would monitor:

1. Ionized calcium (systemic): q4-6h, target 1.0-1.2 mmol/L
2. Total calcium/ionized calcium ratio (Ca:iCa): q12h, target below 2.5
3. pH and bicarbonate: q6-12h, target pH 7.35-7.45, bicarbonate 22-28 mmol/L
4. Magnesium and phosphate: Daily, supplement aggressively
5. Sodium: Daily, manage hypernatremia with free water or hypotonic fluids
6. Liver function: Transaminases, lactate, INR (detect citrate metabolism impairment)

Summary for This Patient:

• Regional citrate anticoagulation is appropriate (oliguric, high bleeding risk in urosepsis)
• Monitor ionized calcium q4-6h to avoid hypocalcemia
• Be aware of citrate-induced alkalosis affecting phenytoin, digoxin, and opioid dosing
• Supplement magnesium and phosphate daily (especially important with meropenem, which can cause seizures if Mg²⁺ low)
• Monitor Ca:iCa ratio q12h; if greater than 2.5, reduce citrate or switch to heparin anticoagulation"

---

Examiner: "Excellent. Thank you for your detailed responses."

---

References

1. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509. PMID: 24768475

2. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3-11. PMID: 25038549

3. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-851. PMID: 19237886

4. De Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380-387. PMID: 24356862

5. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153. PMID: 32383061

6. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. PMID: 20000888

7. Udy AA, Jarrett P, Stuart J, et al. Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Crit Care. 2014;18(6):657. PMID: 25427970

8. Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47(4):421-429. PMID: 11266416

9. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99-110. PMID: 21241071

10. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818. PMID: 16106006

11. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134. PMID: 22738085

12. Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14(1):55-66. PMID: 27924081

13. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31(4):345-351. PMID: 18313273

14. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-1083. PMID: 24429437

15. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126. PMID: 20594297

16. Fudickar A, Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol. 2009;75(5):339-344. PMID: 19412155

17. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-514. PMID: 19586413

18. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. PMID: 32191793

19. Chapman MJ, Nguyen NQ, Deane AM. Gastrointestinal dysmotility: evidence and clinical management. Curr Opin Clin Nutr Metab Care. 2013;16(2):209-216. PMID: 23324899

20. Reintam Blaser A, Malbrain ML, Starkopf J, et al. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 2012;38(3):384-394. PMID: 22310869

21. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock. 2007;28(4):384-393. PMID: 17577136

22. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. PMID: 19176635

23. Alhazzani W, Alshahrani M, Jaeschke R, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2013;17(2):R43. PMID: 23497559

24. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents. 2012;39(5):420-423. PMID: 22445497

25. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975-981. PMID: 21460309

26. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43 Suppl 3:53-59. PMID: 12060006

27. Bauer LA, Blouin RA. Influence of age on aminoglycoside pharmacokinetics in patients without renal disease. Comparison with gentamicin. Eur J Clin Pharmacol. 1981;21(1):39-41. PMID: 7333340

28. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105 Suppl 1:i16-23. PMID: 21148651

29. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87. PMID: 20067334

30. Krahenbuhl S, Reichen J. The pharmacokinetics of drugs in patients with cirrhosis. J Gastroenterol Hepatol. 1992;7(5):522-527. PMID: 1391735

31. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434-438. PMID: 19212314

32. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41(14):1135-1151. PMID: 12405866

33. Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346(8968):145-147. PMID: 7603228

34. Verbeeck RK. Glucuronidation and disposition of drug glucuronides in patients with renal failure. Eur J Drug Metab Pharmacokinet. 1982;7(1):1-7. PMID: 6804322

35. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005;29(5 Suppl):S90-103. PMID: 15907650

36. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377-390. PMID: 1164821

37. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22(2):255-271. PMID: 16678000

38. Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42(3):520-527. PMID: 24201173

39. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137. PMID: 21918498

40. Seyler L, Cotton F, Taccone FS, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137. PMID: 21639901

41. Udy AA, Dulhunty JM, Roberts JA, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled trial. Int J Antimicrob Agents. 2017;49(5):624-630. PMID: 28342860

42. Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care. 2015;19:28. PMID: 25887277

43. Baptista JP, Udy AA, Sousa E, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care. 2011;15(3):R139. PMID: 21651804

44. Gijsen M, Elkayal O, De Waele JJ, Verstraete AG. Pharmacokinetics of antibiotics in critically ill patients with augmented renal clearance: a systematic review. Crit Care. 2023;27(1):214. PMID: 37291590

45. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361(17):1627-1638. PMID: 19846848

46. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995;21(7):612-620. PMID: 7593907

47. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166. PMID: 16163635

---

Summary for CICM Fellowship Candidates

High-Yield PK/PD Concepts:

1. Vd increases 2-3× in sepsis (capillary leak, fluid resuscitation) → Higher loading doses required
2. ARC occurs in 20-65% of ICU patients (CrCl greater than 130 mL/min) → Subtherapeutic antibiotic levels
3. Hypoalbuminemia increases free drug fraction (phenytoin, propofol, valproate) → Measure free levels
4. Loading dose = Vd × Ctarget × Weight (independent of renal function)
5. Maintenance dose = CL × Ctarget (depends on clearance/renal function)
6. Time-dependent killing (beta-lactams): Target %T>MIC greater than 70% with extended/continuous infusion
7. Concentration-dependent killing (aminoglycosides): Target Cmax/MIC greater than 8-10 with high-dose, extended interval
8. AUC-dependent (vancomycin): Target AUC₀₋₂₄ 400-600 mg·h/L with Bayesian dosing
9. CRRT removes drugs with: Low protein binding (below 80%), small Vd (below 1 L/kg), small MW (below 500 Da)
10. Propofol infusion syndrome prevention: Limit below 4 mg/kg/hr TBW, monitor triglycerides, CK, lactate, ECG

Master these concepts, practice calculations, and apply systematic PK/PD reasoning in viva scenarios to excel in CICM Fellowship examinations.